Stock Scorecard
Stock Summary for Catalyst Pharmaceuticals Inc (CPRX) - $22.96 as of 1/16/2026 3:51:12 PM EST
Total Score
14 out of 30
Safety Score
36 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for CPRX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CPRX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CPRX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CPRX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CPRX (36 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 6 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for CPRX
Financial Details for CPRX
Company Overview |
|
|---|---|
| Ticker | CPRX |
| Company Name | Catalyst Pharmaceuticals Inc |
| Country | N/A |
| Description | Catalyst Pharmaceuticals, Inc. is a leading commercial-stage biopharmaceutical company based in Coral Gables, Florida, dedicated to the development and commercialization of novel therapies for rare neuromuscular and chronic neurological disorders. By focusing on high-impact treatments that address significant unmet medical needs, Catalyst aims to enhance the quality of life for patients afflicted by these often-overlooked conditions. The company's innovative approach and robust product pipeline position it favorably within the healthcare sector, making it a compelling investment opportunity for institutional investors interested in transformative advancements in rare disease therapeutics. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/25/2026 |
Stock Price History |
|
| Last Day Price | 22.96 |
| Price 4 Years Ago | 18.60 |
| Last Day Price Updated | 1/16/2026 3:51:12 PM EST |
| Last Day Volume | 1,097,221 |
| Average Daily Volume | 1,302,228 |
| 52-Week High | 26.58 |
| 52-Week Low | 19.05 |
| Last Price to 52 Week Low | 20.52% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 19.60 |
| Sector PE | 43.35 |
| 5-Year Average PE | 19.67 |
| Free Cash Flow Ratio | 4.09 |
| Industry Free Cash Flow Ratio | 12.80 |
| Sector Free Cash Flow Ratio | 31.05 |
| Current Ratio Most Recent Quarter | 6.62 |
| Total Cash Per Share | 5.61 |
| Book Value Per Share Most Recent Quarter | 7.47 |
| Price to Book Ratio | 3.04 |
| Industry Price to Book Ratio | 53.14 |
| Sector Price to Book Ratio | 52.10 |
| Price to Sales Ratio Twelve Trailing Months | 4.83 |
| Industry Price to Sales Ratio Twelve Trailing Months | 19.78 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.91 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 122,912,000 |
| Market Capitalization | 2,822,059,520 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 5.97% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 20.00% |
| Annual Earnings Growth | 129.50% |
| Reported EPS 12 Trailing Months | 1.71 |
| Reported EPS Past Year | 1.28 |
| Reported EPS Prior Year | 1.31 |
| Net Income Twelve Trailing Months | 217,564,000 |
| Net Income Past Year | 163,889,000 |
| Net Income Prior Year | 71,410,000 |
| Quarterly Revenue Growth YOY | 15.30% |
| 5-Year Revenue Growth | 36.89% |
| Operating Margin Twelve Trailing Months | 44.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 689,892,000 |
| Total Cash Past Year | 517,553,000 |
| Total Cash Prior Year | 137,636,000 |
| Net Cash Position Most Recent Quarter | 689,892,000 |
| Net Cash Position Past Year | 517,553,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 727,632,000 |
| Total Stockholder Equity Prior Year | 387,881,000 |
| Total Stockholder Equity Most Recent Quarter | 920,245,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 234,542,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 1.91 |
| Free Cash Flow Past Year | 239,252,000 |
| Free Cash Flow Prior Year | 61,856,000 |
Options |
|
| Put/Call Ratio | 0.19 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.09 |
| MACD Signal | 0.11 |
| 20-Day Bollinger Lower Band | 18.86 |
| 20-Day Bollinger Middle Band | 21.96 |
| 20-Day Bollinger Upper Band | 25.06 |
| Beta | 0.72 |
| RSI | 42.54 |
| 50-Day SMA | 22.35 |
| 150-Day SMA | 18.27 |
| 200-Day SMA | 16.77 |
System |
|
| Modified | 1/14/2026 8:48:15 PM EST |